Study #2024-0243
A phase 2 trial of mosunetuzumab and zanubrutinib for patients with relapsed/refractory marginal zone lymphoma
MD Anderson Study Status
Enrolling
Treatment Agent
Mosunetuzumab, Zanubrutinib
Description
To assess the efficacy and safety of mosunetuzumab combined with zanubrutinib in patients with relapsed or refractory MZL.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Lymphoma
Study phase:
Phase II
Physician name:
Dai Chihara
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-855-581-8877
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.